MAP3K7 and metabolic dysfunction-associated steatotic liver disease: We believe that the upstream molecules that inhibit TAK1-JNK/p38 signaling specifically in the liver, show considerable promise as potential drugs for the treatment of NAFLD or metabolic syndrome.